Breadcrumb
  1. Home
  2. Expanding COVID-19 Response in Rural Communities through Rural Health Clinics
  3. Rural Health Clinic COVID-19 Therapeutics (RHCTH) Program

Rural Health Clinic COVID-19 Therapeutics (RHCTH) Program

Program Summary

The Rural Health Clinic COVID-19 Therapeutics (RHCTH) Program provides access to oral antiviral medications (therapeutics) to eligible CMS-certified Rural Health Clinics (RHCs) by:

  • Supplementing state/jurisdictional allocations of antiviral medications to increase the availability of COVID-19 therapeutics in rural communities.
  • Supplementing state/jurisdictional allocations of antiviral medications to ensure those disproportionately affected by COVID-19 have equitable access to FDA-authorized or approved COVID-19 therapeutics.

HRSA began incremental RHCTH Program enrollment in June 2022 for RHCs already enrolled in the Health Partner Order Portal (HPOP) through participation in the RHC COVID-19 Testing Supply (RHCCTS) Program and/or RHC COVID-19 Vaccine Distribution (RHCVD) Program and with existing legal allowance to prescribe and dispense at point-of-care or with pharmacy capacity.

As of July 2022, additional RHCs may enroll in the RHCTH Program regardless of current HPOP enrollment or participation in other RHC COVID-19 programs.

Eligibility

  • CMS-certified RHCs and organizations that own and operate CMS-certified RHCs.
  • All RHCs must have active CMS Certification Numbers (CCNs).

Enrollment

  1. Verify your RHC provider type eligibility and obtain your RHC CCN on the CMS Quality, Certification and Oversight Reports (QCOR) website;
  2. Once your RHC CCN is confirmed, email RHCtreatment@hrsa.gov for additional enrollment instructions.

HRSA will enroll RHCs in the Therapeutics Program as they meet eligibility requirements. You will receive an email confirmation once enrolled.

Technical Assistance

Contact

For questions about the RHC COVID-19 Therapeutics Program, email RHCTreatment@hrsa.gov.

Date Last Reviewed: